Graduate School of Converging Clinical & Public Health, Ewha Womans University, Seoul, 03760, South Korea.
Department of Pharmacy, Korea Veterans Hospital, Seoul, 05368, South Korea.
BMC Geriatr. 2018 Nov 29;18(1):293. doi: 10.1186/s12877-018-0990-1.
Risk factors associated with opioid-induced adverse reactions (OIARs) in the elderly population have not been well defined. The objective of this study was to determine effects of various risk factors on incidence of OIARs in male elderly patients.
A retrospective cohort study in Korea Veterans Hospital was performed. Data were analyzed in male patients aged 65 years and older who received morphine, oxycodone, or codeine. Binomial variables describing patient-related and drug-related characteristics were constructed. Associations between these variables and frequency of OIARs were determined. Odds ratio (OR) and adjusted odds ratio (AOR) were calculated from univariate and multivariable analyses, respectively. Attributable risk was obtained by (1-1/OR)*100%.
Of 316 patients, 28% experienced at least one adverse event. The most common adverse events were gastrointestinal problems (n = 59) and central nerve system adverse effects (n = 20). The odds of OIARs in patients with opioid use ≥12 weeks was increased by 80% compared to those with opioid use < 12 weeks. Attributable risk of GABA analogues was 64~78% in constructed Models. Compared to codeine users, patients using morphine and oxycodone had 653 and 473% increased odds for OIARs, respectively. MME ≥ 60 mg/day had a 317% increased odds for OIARs (95% CI: 1.92-9.04) compared to MME < 60 mg/day. Opioid combination therapy had a 139% increased odds for OIARs compared to monotherapy.
These findings have significant implications for clinical use of opioid in elderly patients. Our study suggests that low dose short-term use will pose less risk of OIARs for the elderly, whereas concomitant use of GABA analogues, strong opioids and dual-opioid therapy may increase the risk of OIARs. Therefore, clinician should carefully monitor patients when starting opioid therapy in older population.
与老年人群中阿片类药物引起的不良反应(OIARs)相关的风险因素尚未得到很好的定义。本研究的目的是确定各种风险因素对老年男性患者 OIARs 发生率的影响。
在韩国退伍军人医院进行回顾性队列研究。对接受吗啡、羟考酮或可待因的年龄在 65 岁及以上的男性患者进行数据分析。构建描述患者相关和药物相关特征的二项变量。确定这些变量与 OIAR 频率之间的关联。使用单变量和多变量分析分别计算比值比(OR)和调整比值比(AOR)。归因风险通过(1-1/OR)*100%获得。
在 316 名患者中,28%至少经历了一次不良反应。最常见的不良反应是胃肠道问题(n=59)和中枢神经系统不良反应(n=20)。与阿片类药物使用<12 周的患者相比,阿片类药物使用≥12 周的患者 OIAR 发生的几率增加了 80%。在构建的模型中,GABA 类似物的归因风险为 64%至 78%。与可待因使用者相比,使用吗啡和羟考酮的患者 OIAR 的几率分别增加了 653%和 473%。与 MME<60mg/天相比,MME≥60mg/天发生 OIAR 的几率增加了 317%(95%CI:1.92-9.04)。与单药治疗相比,阿片类药物联合治疗 OIAR 的几率增加了 139%。
这些发现对老年患者阿片类药物的临床应用具有重要意义。我们的研究表明,对于老年人来说,低剂量短期使用不太可能引起 OIARs,而同时使用 GABA 类似物、强阿片类药物和双重阿片类药物治疗可能会增加 OIARs 的风险。因此,当在老年人群中开始阿片类药物治疗时,临床医生应仔细监测患者。